A Blood Test May Reveal Who Responds Best to Alzheimer’s Drug Lecanemab
Blood pressure, not brain scans, best predicted which patients cleared a key Alzheimer’s biomarker fastest after starting lecanemab, a Korea University study of 153 patients found, months before cognitive scores showed any difference.